Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

UK researchers track Real-World success of CLL drug acalabrutinib

NCT ID NCT05557695

Knowledge-focused Sponsor: AstraZeneca Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Sep 10, 2026 · Updated 2 times

Summary

This study observes about 350 people with chronic lymphocytic leukemia (CLL) who received the drug acalabrutinib through a UK early access program. Researchers will review medical records to see how long patients went without their cancer worsening and how long they lived. No new treatments are given; the goal is to learn how well acalabrutinib works in everyday practice.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 287 people

The number the study aims to enrol. It can still change while the study runs.

Started

Oct 2022

Expected to finish

Apr 2027

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Treatment-naïve adults (≥18 years old) with chronic lymphocytic lymphoma (CLL) who were initiated on acalabrutinib as part of the UK acalabrutiinib early access programme and received their first dose of acalabrutinib between 1 April 2020 and 1 April 2021.

Ages

18 to 130 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

The study population will include treatment-naïve patients with chronic lymphocytic lymphoma (CLL)\* who meet the following inclusion criteria: * Treatment-naïve CLL patients who were initiated on acalabrutinib as part of the UK Early Access Programme * Received their first dose of acalabrutinib between 1 April 2020 and 1 April 2021 * Patients aged ≥18 years old * Note: patients later found to have small lymphocytic lymphoma (SLL) may also be included in the EAP. Exclusion Criteria: \- None listed in study protocol

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Chronic lymphocytic leukemia (CLL) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

B-cell chronic lymphocytic leukemia Leukemia, B-Cell

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Chronic lymphocytic leukemia (CLL)

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    29 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Research Site

    RECRUITING

    Aylesbury, United Kingdom

  • Research Site

    RECRUITING

    Bath, United Kingdom

  • Research Site

    RECRUITING

    Birmingham, United Kingdom

  • Research Site

    RECRUITING

    Bournemouth, United Kingdom

  • Research Site

    RECRUITING

    Cardiff, United Kingdom

  • Research Site

    RECRUITING

    Cornwall, United Kingdom

  • Research Site

    RECRUITING

    Dartford, United Kingdom

  • Research Site

    RECRUITING

    Derby, United Kingdom

  • Research Site

    RECRUITING

    Doncaster, United Kingdom

  • Research Site

    RECRUITING

    Dorset, United Kingdom

  • Research Site

    RECRUITING

    Eastbourne, United Kingdom

  • Research Site

    RECRUITING

    Hull, United Kingdom

  • Research Site

    RECRUITING

    Leicester, United Kingdom

  • Research Site

    RECRUITING

    Lincoln, United Kingdom

  • Research Site

    RECRUITING

    Liverpool, United Kingdom

  • Research Site

    RECRUITING

    London, SE1 9RT, United Kingdom

  • Research Site

    RECRUITING

    London, W12 OHS, United Kingdom

  • Research Site

    RECRUITING

    Mid Yorkshire, United Kingdom

  • Research Site

    RECRUITING

    Middlesbrough, United Kingdom

  • Research Site

    RECRUITING

    Newcastle, United Kingdom

  • Research Site

    RECRUITING

    North Shields, United Kingdom

  • Research Site

    RECRUITING

    Norwich, United Kingdom

  • Research Site

    RECRUITING

    Nottingham, United Kingdom

  • Research Site

    RECRUITING

    Oxford, United Kingdom

  • Research Site

    RECRUITING

    Plymouth, United Kingdom

  • Research Site

    RECRUITING

    Southampton, United Kingdom

  • Research Site

    RECRUITING

    Stockton-on-Tees, United Kingdom

  • Research Site

    RECRUITING

    Stoke-on-Trent, United Kingdom

  • Research Site

    RECRUITING

    Wigan, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.